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of life are important in clinical care and research studies. The MacNew
Heart Disease health-related quality of life questionnaire has been val-
idated in English-speaking patients with myocardial infarction. The
aim of this study was to validate the MacNew in English-speaking pa-
tients with angina or ischemic heart failure. Methods: Canadian and
merican patients with angina or ischemic heart failure completed the
acNew, the Short Form-36 Health Survey, and the Hospital Anxiety
nd Depression Scale. Results: We administered questionnaires to 276
atients with angina (mean age, 65.9 years) and 155 patients with isch-
mic heart failure (mean age, 70.3 years). The mean  SD MacNew
global score in patients with ischemic heart failure (5.1  1.2) was sta-
tistically (P  0.001), but not clinically, poorer than in patients with
angina (5.3  1.1). The three-factor measurement model explained
46.1% of the observed variance in the MacNew in patients with angina
and 46.5% in patients with ischemic heart failure. Internal consistency
ivers
al So
oi:10.1016/j.jval.2011.07.003was 0.90, and test-retest reliability was 0.70 for each MacNew scale
and the a priori convergent and discriminative validity hypotheses
were confirmed in both diagnoses. The MacNew was highly accepted
by patients with little respondent or administrative burden.
Conclusions: The English version of the MacNew is reliable and valid
in patients with angina or ischemic heart failure. This permits health-
related quality of life outcome comparisons in patients with angina,
ischemic heart failure, and myocardial infarction with the MacNew
and provides a better understanding of the full range of health-related
quality of life outcomes.
Keywords: angina pectoris, coronary artery disease, health status, isch-
emic heart failure, patient-reported outcomes, quality of life, question-
naire.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Patientswith ischemic heart disease (IHD) present on a continuum
of events that includes the presence of risk factors, angina, myo-
cardial infarction (MI), and ischemic heart failure, often with
marked health-status deficits including poor health-related qual-
ity of life (HRQoL). As the patient’s own perspective of the impact
of disease and its treatment, patient-reported outcome measures
such as HRQoL have been recommended in both clinical care and
research studies by the National Heart, Lung and Blood Institute
[1], the U.S. Food and Drug Administration [2], and the European
Medicines Agency [3]. Generic HRQoL outcome measures permit
assessment of awide range of aspects of life applicable to a variety
of health states and are useful in conducting general health survey
research [4]. Specific HRQoL outcome measures focus on disease-
relevant issues and are appropriate outcome measures in both
therapeutic intervention trials [4] and routine clinical care [5] but
should be used only in patients with the disease/diagnosis for
* Address correspondence to: Stefan Höfer, Innsbruck Medical Un
E-mail: stefan.hoefer@i-med.ac.at.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.which the instrument is validated and not with an “off-label diag-
nosis.”
A core disease-specific HRQoL questionnaire approach with
adequate generalizability and sufficient specificity has been avail-
able for about two decades to make between-diagnosis outcome
comparisons, for example, in oncology [6,7] and rheumatology [8].
Between-diagnosis HRQoL outcome comparisons are not possible
with commonly used IHD diagnosis-specific questionnaires with
specific cues such as “your chest pain, chest tightness, or angina”
in the Seattle Angina Questionnaire [9] and “your heart failure” in
the Minnesota Living with Heart Failure Questionnaire [10]. In-
creasingly, patients with different IHD diagnoses receive similar
treatment, e.g., medication, percutaneous or surgical revascular-
ization, and referral to secondary prevention cardiac rehabilita-
tion, often with common therapeutic goals including symptom
management and improvement of HRQoL [1]. A core IHD-specific
HRQoL questionnaire with a cue such as “your heart problem”
would be useful in clinical practice and research studies allowing
between-diagnosis treatment outcome comparisons, would be ef-
ity, Speckbacherstr. 23/3, 6020 Innsbruck, Austria.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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144 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 4 3 – 1 5 0ficient, and would provide a better understanding of the range of
HRQoL in patients with different IHD diagnoses.
The interviewer-administered Quality of Life after Myocardial
Infarction questionnaire was designed to evaluate how MI and its
treatment affects patients’ daily life and was validated [11] in Eng-
lish-speaking Canadian patients participating in a randomized
trial of cardiac rehabilitation [12]. This questionnaire was subse-
quently modified as the self-administered MacNew Heart Disease
HRQoL questionnaire and validated in English-speaking Austra-
lian patients with MI [13,14]. The MacNew has since been trans-
lated into 28 languages with independently published validation
studies in 8 of these languages in patients with MI (n  4300),
ngina (n  1800), and ischemic heart failure (n  550) [15–26].
As the psychometric properties demonstrated in patients with
I [27] have been replicated in non–English-speaking patients
ith angina or ischemic heart failure [17–20,22,23,26], theMacNew
ay provide a core IHDHRQoL questionnaire formaking between-
iagnosis comparisons of HRQoL outcomes. There are no valida-
ion studies, however, of theMacNew in English-speaking patients
ith either angina or ischemic heart failure. The objective of this
tudywas therefore to investigate the reliability and validity of the
nglish version of theMacNew in patientswith angina or ischemic
eart failure.
Methods
Patients
English-speaking patients with a diagnosis of angina or ischemic
heart failure were recruited in Canada and the United States as
part of the HeartQoL Project, an international survey of HRQoL in
more than 6300 patients with IHD in Australia, Europe, and North
America [28]. Institutional review boards approved the HeartQoL
roject at each site, and informed consent was obtained from all
ubjects.
A convenience sample of patients 18 years of age and older able
to complete the self-administered battery of HRQoL instruments
in English, without serious psychiatric disorder, and not a sub-
stance abuser were eligible if they had a diagnosis of and being
treated for either:
Angina (Canadian Cardiovascular Society Grade II [slight limi-
tation of ordinary physical activity], grade III [marked limitation of
ordinary physical activity], or grade IV [inability to carry on any
physical activity without discomfort] [29]) with an objective mea-
sure of IHD (e.g., previous MI, exercise testing, echocardiography,
nuclear imaging, angiography) or ischemic heart failure (NewYork
Heart Association functional class II [patients with cardiac disease
resulting in slight limitation of physical activity], functional class
III [patients with cardiac disease resulting in marked limitation of
physical activity], or functional class IV [patients with cardiac dis-
ease resulting in the inability to perform any physical activity
without discomfort] [30]) with evidence of left ventricular dysfunc-
tion (ejection fraction 40% by invasive or noninvasive testing)
nd an objective measure of IHD (e.g., previous MI, exercise test-
ng, echocardiography, nuclear imaging, angiography).
Questionnaires
The referring physician completed a questionnaire for routine di-
agnostic data, and all patients completed a self-report sociodemo-
graphic and clinical questionnaire, including health behaviors. In
addition, the Short Form-36 Health Survey (SF-36), the Hospital
Anxiety andDepression Scale (HADS), and theMacNewwere com-
pleted by all patients at baseline and again 2 weeks later by the
first approximately 20% of the patients whom the site investigator
considered to be in a stable condition.SF-36
The SF-36 is an internationally validated generic health survey
[31]. It consists of 36 itemswith 8 subscales summarized in a phys-
ical component summary (PCS) and a mental component sum-
mary (MCS) scale [32].
HADS
The HADS is a validated psychological screening instrument de-
signed to screen for symptoms of anxiety and depression [33]. It is
responsive and has been extensively used internationally in clin-
ical trials with scores of 8 or higher used to classify patients with
symptoms of depression or anxiety [34].
MacNew
The MacNew is designed to assess patient’s feelings about how
IHD affects daily functioning and contains 27 items with a global
HRQoL score and physical limitation, emotional, and social func-
tion subscales [13,14], with a summary of international results
available [35]. The items and scales are scored from 1 (low HRQoL)
to 7 (high HRQoL), and the minimal important difference (MID) on
each MacNew scale is 0.50 points [36]. The readability level of the
English MacNew has been established to be on average between
the fifth and sixth grade level [37].
Statistical analysis
Patient clinical and sociodemographic characteristics are de-
scribed as either dichotomous or continuous variables. HRQoL
scale scores (mean  SD) were calculated using established scor-
ing criteria for each instrument. Comparisons between the two
cardiac diagnostic groups were made using analysis of variance
(ANOVA) (continuous variables) and chi-square (2) (categorical
ariables). Assumption for ANOVA (normality and homoschedac-
ty) was tested by Kolmorgorov-Smirnov, skewness, and kurtosis
tatistics. If data did not meet the necessary criteria, the Welch
est (F) was used or the nonparametric Kruskal-Wallis H test was
pplied.
Using recommended criteria [38] as described in detail below,
he conceptual model, reliability, validity, interpretability, and re-
pondent and administrative burden of the MacNew were as-
essed for patients with angina and for patients with ischemic
eart failure. Face and content validity of the MacNew has been
reviously documented [35].
The original factor structure identified by Valenti et al. [14] was
he basis for the confirmatory factor analysis that was carried out
sing AMOS 18 [39]. Because 2 statistics are dependent on sample
ize, a recommended range of parameters less sensitive to sample
izewasselected.The2/df, rootmeansquareerrorof approximation
RMSEA) and comparative fit index (CFI) were used to evaluate data
t. Acceptable values are5 for 2/df [40],0.90 for the CFI and0.08
or the RMSEA,with anRMSEAof 0.0 indicating a perfect, 0.05 a good,
nd 0.08 a reasonable fit [41]. Measurement errors of the items were
llowed to intercorrelate where appropriate. Further, differential
tem functioning (DIF) was assessed [42]. A DIF analysis assesses
hether items are functioning equivalently across important cate-
ories, such as diagnosis (angina or ischemic heart failure). A mini-
umdifference inscoresof 0.5 logits (P0.01)wasused.DIFanalysis
as performed usingWINSTEPS 3.67 [43].
Internal consistency (Cronbach ) and 14-day test-retest reli-
ability (intraclass correlation coefficient [ICC])were assessed using
r  0.70 as the criterion value for both tests. With a priori predic-
tions hypothesizing strong correlations between similar SF-36 and
MacNew constructs and significantly lower correlations between
dissimilar constructs (0.10 absent, 0.10–0.29weak, 0.30–0.49
moderate, and 0.50  strong), we tested the MacNew for con-
struct validity using Steiger’s test for comparing Pearson correla-
tions coefficients [44,45]. We assessed discriminative validity [46]
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145V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 4 3 – 1 5 0testing the hypotheses that HRQoL would be 1) poorer in anxious
and depressed patients than those who were not using the HADS
and 2) poorer in patients who perceived that their health had or
had not deteriorated over the past year using the SF-36 health
transition item. We also report on the interpretability of the
MacNew scores relative to the published MacNew MID (0.5
points) and on respondent and administrative burden.
SPSS version 16.0 (SPSS, Inc., Chicago, Illinois) was used for all
statistical analyses. Statistical significance was established at P 
0.05.
Results
Patient characteristics (Table 1)
A convenience sample of 431 patients was recruited with a mean 
SD age of 67.5  11.9 years, and 297 (68.9%) were male. The mean 
SD age in the 276 patients with angina was 65.9  11.4 years and
70.3 2.3 years in the 155 patientswith ischemic heart failure. In the
ngina group, 13.0% reported they were current smokers and 54.5%
xercised less than three times per week; 69.9% reported that their
hysician had told them theywere hypertensive, 30.1%diabetic, and
Table 1 – Sociodemographic and clinical characteristics
of patients with angina and patients with ischemic
heart failure.
Patient
characteristics
Angina
(n  276)
IHF
(n  155)
Age in years 65.9  11.4 70.3  12.3
Sex
Male 171 (62.0) 124 (80.0)
Female 105 (38.0) 31 (20.0)
Family status
Single 45 (16.3) 20 (12.9)
Married 180 (65.2) 102 (65.8)
Other 41 (14.9) 32 (20.6)
Employment
White collar 122 (44.2) 75 (48.4)
Blue collar 96 (34.8) 45 (29.0)
Education
Less than high
school
55 (19.9) 41 (26.5)
High school 100 (36.2) 55 (35.5)
More than high
school
120 (43.5) 58 (37.4)
Anxious (HADS
score8)
76 (27.5) 33 (21.3)
Depressed (HADS
score 8)
56 (20.4) 36 (23.0)
Body mass index 29.5  6.5 28.5  6.0
Smoker 36 (13.0) 21 (13.5)
Functional status
CCS II: 154 (55.8) NYHA II: 56 (36.1)
CCS III: 100 (36.2) NYHA III: 87 (56.1)
CCS IV: 11 (4.0) NYHA IV: 6 (3.9)
Hypertensive 193 (69.9) 105 (67.7)
Diabetic 83 (30.1) 65 (41.9)
Hypercholesterolemia 205 (74.3) 101 (65.2)
Physically inactive* 150 (54.5) 113 (73.0)
Values shown are mean  SD or number (%). Data missing when
100%. CCS, Canadian Cardiovascular Society; HADS, Hospital
Anxiety and Depression Scale; IHF, ischemic heart failure; NYHA,
New York Heart Association (functional class).
* Exercised less than three times/week.4.3% with high cholesterol. In the ischemic heart failure group,3.5% reported they were current smokers and 73.0% exercised less
han three times per week; 67.7% reported that their physician had
old them they were hypertensive, 41.9% diabetic, and 65.2% with
igh cholesterol. There were no patients with either Canadian Car-
iovascular Society or NewYork Heart Association functional class I
er study design, and only a few with Canadian Cardiovascular So-
iety angina class IV (4.0%) or NewYork Heart Association heart fail-
re functional class IV (3.9%).
MacNew, SF-36 health status, anxiety, and depression
(Table 2)
MacNew subscale scores could be calculated in all 431 patients,
SF-36 subscale scores in 409 patients (94.9%), and HADS scale
scores in 427 patients (99.1%).
Patientswith angina had better HRQoL than patientswith isch-
emic heart failure with significantly higher scores on the MacNew
global, physical, and social subscales and on the SF-36 PCS but not
the MCS. The HADS anxiety scores and depression scores did not
differ significantly between patients with angina and those with
ischemic heart failure.
MacNew questionnaire item characteristics (Table 3)
ThemissingMacNew item rate ranged from 0% (shortness of breath
item) to 108 (39.1%) in patientswith angina and 77 (49.7%) in patients
with ischemic heart failure (sexual activity item for both groups).
More than oneMacNew itemwasmissed by 42 of the patients (9.7%),
with only one patient missing as many as seven items. Therefore,
eachMacNew subscale could be scored for every patient. Therewere
no floor effects for the MacNew global score or subscales in patients
with either angina or ischemic heart failure. Ceiling effects were ob-
served in 1.3% of the patients on the global scale and the physical
and emotional subscales; ceiling effectswere observed in 16 (5.8%) of
patients with angina and 6 (3.9%) in patients with ischemic heart
failure on the social subscale for both groups.
MacNew factor structure (Table 4)
Our findings confirm the multidimensionality of the MacNew and
support the established three-factor MImodel [13,14]. After allow-
ing measurement errors of the items to intercorrelate where ap-
propriate, the three-factor model was supported for the combined
data (2/df  3.66; CFI  0.938, RMSEA  0.063, explained variance
Table 2 – MacNew, SF-36 physical component and
mental component scales, and HADS scores in patients
with angina and patients with ischemic heart failure.
Angina IHF P value*
MacNew
Global 5.3  1.1 5.1  1.2 0.045
Physical 5.3  1.2 4.9  1.4 0.003
Emotional 5.3  1.1 5.2  1.2 0.434
Social 5.5  1.2 5.1  1.4 0.001
SF-36
PCS 39.7  11.3 35.8  10.1 0.001
MCS 49.5  10.8 49.1  10.9 0.715
HADS
Anxiety 5.8  3.5 5.4  3.4 0.336
Depression 4.6  3.5 5.1  3.8 0.303
.
HADS, Hospital Anxiety and Depression Scale; IHF, ischemic heart
failure; MCS, mental component summary; PCS, physical compo-
nent summary; SF-36, Short Form-36 Health Survey.
* Kruskal-Wallis H test.
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146 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 4 3 – 1 5 045.9%), for patients with angina (AP: 2/df 2.41, CFI  0.918,
MSEA  0.072, explained variance 46.1%), and for patients with
schemic heart failure (IHF: 2/df  2.08, CFI  0.903, RMSEA 
0.080, explained variance 46.5%). The intercorrelation of the fac-
tors ranged from 0.61 to 0.72. In both of the original MacNew factor
Table 3 – MacNew global and subscale floor and ceiling eff
reliability in patients with angina and patients with ischem
Global
Angina
Floor effects, % 0
Ceiling effects, % 0.4
Cronbach  0.96
ICC (95% CI) (n  62) 0.72 (0.57–0.82) 0
Ischemic heart failure
Floor effects, % 0
Ceiling effects, % 0.6
Cronbach  0.97
ICC (95% CI) (n  22) 0.85 (0.68–0.94) 0
CI, confidence interval; ICC, intraclass correlation.
Table 4 – Confirmatory factor analysis for each MacNew ite
MacNew item
Angina
Emo Phys
1. Frustrated 0.78 —
2. Worthless 0.64 —
3. Confident 0.60 —
4. Down in the dumps 0.85 —
5. Relaxed 0.78 —
6. Worn out 0.41 0.36
7. Happy with personal
life
0.77 —
8. Restless 0.69 —
9. Shortness of breath — 0.68
10. Tearful 0.63 —
11. More dependent — —
12. Social activities 0.05 0.35
13. Less confidence in you 0.29 —
14. Chest pain — 0.41
15. Lack self-confidence 0.54 —
16. Aching legs — 0.40
17. Sports/exercise limited — 0.99
18. Frightened 0.72 —
19. Dizzy or lightheaded — 0.45
20. Restricted or limited — 0.93
21. Unsure about exercise — 0.68
22. Overprotective family — —
23. Burden on others 0.20 —
24. Excluded — 0.47
25. Unable to socialize — 0.46
26. Physically restricted — 0.97
27. Sexual activity — —
Variance explained, % 19.5 18.3
Factor loading items shown in bold type differ from original factor lo
Emo, emotional subscale; Phys, physical subscale; Soc, social subscale.analyses based on patients with MI [13,14], a high proportion of
social subscale items (10 of 13) cross-loaded with more than one
subscale with factor loadings 0.40. In the current analysis, none
of the social subscale items cross-loaded in the physical or emo-
tional subscales with loadings 0.40 in patients with angina; only
internal consistency (Cronbach ), and test-retest
eart failure.
MacNew
sical Emotional Social
0 0
.4 0.4 5.8
.93 0.94 0.94
55–0.81) 0.75 (0.62–0.84) 0.72 (0.57–0.82)
0 0
.3 0.6 3.9
.94 0.95 0.95
68–0.96) 0.78 (0.55–0.90) 0.86 (0.69–0.94)
patients with angina and ischemic heart failure.
Diagnosis
Ischemic heart failure
Soc Emo Phys Soc
— 0.81 — —
0.26 0.79 — 0.13
— 0.65 — —
— 0.87 — —
— 0.76 — —
— 0.40 0.48 —
— 0.72 — —
— 0.78 — —
— — 0.83 —
— 0.65 — —
0.65 — — 0.67
0.30 0.32 0.32 0.11
0.49 0.44 — 0.38
— — 0.53 —
0.33 0.69 — 0.20
— — 0.65 —
—
0.15
— 0.64 0.33
— 0.78 — —
— — 0.43 —
—
0.07
— 0.67 0.34
0.08 — 0.46 0.42
0.55 — — 0.56
0.68 0.42 — 0.46
0.38 — 0.30 0.61
0.38 — 0.55 0.33
—
0.07
— 0.66 0.36
0.49 — — 0.55
8.3 23.2 14.1 9.2
in patients with myocardial infarction.ects,
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ical subscale with a loading 0.40 in patients with ischemic heart
failure. Item 27 about sexual activity, which was not part of the
original factor analysis [14], fitted best with the social subscale. No
DIF was observed for diagnosis, except for item 14 (DIF  0.55
logits, t(6.21), P  0.001, Fig. 1).
MacNew reliability (Table 3)
Internal consistency reliability of the MacNew global and each
subscale was confirmed with all Cronbach  values 0.90 in pa-
ients with each diagnosis. As a measure of test-retest reliability,
he ICC was always0.70, ranging from 0.70 (physical subscale) to
.75 (emotional subscale) in patients with angina and from 0.78
emotional subscale) to 0.90 (physical subscale) in patients with
schemic heart failure.
MacNew convergent validity (Table 5)
The correlations between similar MacNew and SF-36 scales
(MacNew physical and PCS; MacNew emotional and MCS) were
significant (P  0.001), strong, and in the hypothesized direction.
The correlations between dissimilar MacNew and SF-36 scales
were significantly lower than between the similar scales (all one-
sided P values 0.05). Taken together, these results confirm the
convergent validity of the MacNew scales in patients with angina
and ischemic heart failure.
MacNew discriminative validity (Table 6)
Discriminative validity of the MacNew was confirmed for each
criterion (P  0.001) in patients with angina and in patients with
schemic heart failure. In addition, all MacNew score differences
xceeded the MID criterion of 0.5 between 1) the two diagnostic
groups, 2) those improving or staying the same and those deteri-
orating on the SF-36 health transition item (always 0.88 in pa-
tients with angina and 1.24 in patients with ischemic heart fail-
ure), 3) those with and without anxiety (always 1.02 in patients
with angina and1.27 in patientswith ischemic heart failure), and
4) those with and without depression (1.45 in patients with an-
gina and 1.91 in patients with ischemic heart failure).
Discussion
The English-language MacNew Heart Disease HRQoL question-
naire meets the recommended psychometric criteria for the con-
ceptual model, reliability, validity, interpretability, and burden
[38] in patients with either angina or ischemic heart failure. The
expected patterns in MacNew global and each subscale scores
were confirmed as patients with ischemic heart failure had poorer
Fig. 1 – Differential item function for angina (AP) and heart f
is presented in logits.scores than patients with angina. These findings substantiate val-idation reports on theMacNew in other languages in patients with
angina and ischemic heart failure [24,26] as well as in patients
with MI [13,14,16,21,26], providing support for the notion of the
MacNew as a core IHD disease-specific HRQoL questionnaire.
The three-factor physical, emotional, and social subscale
structure of the original English MacNew in patients with MI was
confirmed in these patients with either angina or ischemic heart
failure. In patients with angina, 46.1% of the total observed vari-
ance was explained, with 46.5% explained in patients with isch-
emic heart failure. The results of this confirmatory factor analysis
indicate that the emotional and physical subscales are most con-
sistentwith the original factor structure identified in patientswith
MI [14]; only two emotional items (items 13 and 23) and one phys-
ical item (item 6) in patients with angina and only one physical
subscale item (item 24) in patients with ischemic heart failure
differed from the original factor analysis. Cross-loadings of 0.40
were allowed in the originalmodelwith 11 of the 13 social subscale
items associated with either physical or emotional items [14],
none of which were substantiated in the current study in patients
with either angina or ischemic heart failure. In fact, the item about
social activities (item 12) showed cross-factor loadings of 0.40,
hich is quite different from the originalmodel inwhich itwas the
nly item with cross-loadings of 0.40 on all three subscales [14].
Table 5 – Convergent validity of the MacNew physical
and emotional subscales with the SF-36 physical
component and mental component scales in patients
with angina (n = 262) and patients with ischemic heart
failure (n = 147).
MacNew
physical
subscale
MacNew
emotional
subscale
One-sided
P value*
Angina
SF-36 PCS 0.728† 0.510† 0.001
SF-36 MCS 0.490† 0.731† 0.001
One-sided P value* 0.001 0.001
Ischemic heart failure
SF-36 PCS 0.743† 0.632† 0.035
SF-36 MCS 0.584† 0.750† 0.004
One-sided P value* 0.007 0.026
Strong correlations, r  0.50.
SF-36 MCS, Short Form-36 Health Survey mental component sum-
mary; SF-36 PCS, Short Form-36 Health Survey physical component
summary.
* Steiger’s test for comparing Pearson correlation coefficients.
e (HF) patients. Differential item functioning (DIF) measureailur† Pearson correlation coefficients; P values 0.001.
148 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 4 3 – 1 5 0Item 27 about sexual activity was not part of the original factor
structure [13,14] and, consistent with more recent international
factor analysis studies [17, 21,23], fell into the social subscale
rather than the physical subscale. A potential explanation for
these findings is that the MacNew social items in general relate to
social situations, either in a physical or interpersonal (emotional)
context. These observations and concerns expressed previously
about the factor structure of the MacNew [47,48] suggest that re-
visiting the MacNew from both a modeling perspective allocating
items only to their main subscale and an item reduction perspec-
tivewould be productive. This is in the process of being addressed.
No differential item functionwas detected except for item 14. Item
14 addresses “how often during the past two weeks have you ex-
perienced chest pain while doing your day-to-day activities,”
which was more likely to be endorsed by angina patients than
ischemic heart failure patients.
Consistent with MacNew internal consistency reports in other
languages [17,19,21–27], the Cronbach was 0.90 on all scales in
eachdiagnosis allowing for both group and individualHRQoL com-
parisons [38,49]. When administered twice, 14 days apart, test-
retest reliability was confirmed in both diagnoses with an ICC
0.70 on all MacNew scales, also consistent with MacNew reports
in other languages [22–24,26]. The lower test-retest reliabilities ob-
served in patients with angina than in those with ischemic heart
failure are most likely explained by the fluctuating nature of chest
pain, even when well managed.
Convergent and discriminative validity of the MacNew was
confirmed in patients with angina or ischemic heart failure. Sim-
ilarMacNewand SF-36 scales (MacNewphysical and PCS;MacNew
emotional andMCS) had significantly high correlations. Dissimilar
scales (MacNew physical and MCS; MacNew emotional and PCS)
Table 6 – Discriminant validity of MacNew global score and
anxiety and depression in patients with angina and patien
Global
Angina
SF-36 health transition
Improve 5.62  0.9*
No change 5.61  0.8†
Deteriorate 4.65  1.2
Anxiety
No 5.63  0.9
Yes 4.49  1.1‡
Depression
No 5.63  0.8
Yes 4.11  1.0‡
Ischemic heart failure
SF-36 health transition
Improve 5.51  0.9*
No change 5.51  0.9†
Deteriorate 4.20  1.1
Anxiety
No 5.41  1.0
Yes 3.95  1.2‡
Depression
No 5.53  0.9
Yes 3.61  0.8‡
Values shown are mean  SD. Analysis of variance (Welch test) or K
HADS, Hospital Anxiety and Depression Scale; SF-36, Short Form-36
* Improve vs. deteriorate; P  0.05.
† No change vs. deteriorate; P  0.05.
‡ P  0.001 in each diagnosis.had significantly lower correlations than those of the similarscales. The MacNew discriminated significantly by SF-36 health
transition status, anxiety, and depression in both diagnostic
groups. Patients with perceived health deterioration over the past
year had significantly poorer MacNew global HRQoL and subscale
scores than patients whose health had improved or stayed the
same, with the difference exceeding the MacNew MID criterion of
0.5 points [36]. SimilarMacNew observationswere observed by the
presence or absence of anxiety or depression, with the differences
also exceeding theMID criterion in each instance. As an extension
of these observations, the sample size required to demonstrate
HRQoL differences between depressed and nondepressed patients
with the specificMacNewHRQoL instrumentwould be only 40% of
that estimated for the generic SF-36 HRQoL instrument (MacNew,
n  8 per group vs. SF-36, n  22 per group), and this observation
holds true for depression and for health transition status. This is
important in terms of the potential usefulness of the MacNew
because sample size is a major consideration when designing
high-cost randomized trials.
Item relevance and minimal respondent and administrative
burden are fundamental to the acceptance, implementation, and
utilization of HRQoL instruments by patients, clinicians, and re-
searchers [38]. That only 1 of the 431 patientsmissed nomore than
7 of the 27 MacNew items in this study clearly demonstrates the
relevance of items to patients, and MacNew global and subscale
scores could be calculated for each of the 431 patients. Patients
with cardiovascular disease frequently report fatigue [50]. “Feeling
worn out” (MacNew item 6) was reported to be the number one
problembypatients in both diagnostic groups in the current study,
suggesting that fatigue can be considered a potential treatment
focus for many patients with angina or ischemic heart failure.
scale scores by SF-36 health status transition and HADS
ith ischemic heart failure.
MacNew
hysical Emotional Social
.67  1.0* 5.55  1.0* 5.84  1.0*
.53  0.9† 5.56  0.8† 5.89  1.0†
.51  1.3 4.66  1.3 4.73  1.3
.53  1.1 5.65  0.9 5.80  1.0
.58  1.3‡ 4.32  1.1‡ 4.77  1.4‡
.56  1.0 5.63  0.8 5.83  0.9
.10  1.2‡ 3.92  1.0‡ 4.24  1.3‡
.41  1.2* 5.57  1.0* 5.51  1.1*
.29  1.2† 5.60  1.0† 5.60  1.2†
.88  1.2 4.33  1.2 4.05  1.3
.16  1.3 5.56  0.9 5.38  1.2
.88  1.3‡ 3.82  1.2‡ 3.96  1.5‡
.36  1.0 5.62  0.8 5.56  1.1
.27  0.8‡ 3.70  1.0‡ 3.44  0.9‡
l-Wallis H test.
h Survey.sub
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149V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 1 4 3 – 1 5 010 minutes and is simple to score, resulting in minimal respon-
dent and administrative burden [35].
The major limitation to this study is that the parent HeartQoL
roject was designed as a cross-sectional survey for recruiting
onvenience samples of patients at each site [28]. As a result, we
re unable to generate and report responsiveness statistics for the
acNew in these patients with either angina or ischemic heart
ailure. Although some ceiling effect was observed on the social
ubscale, the minimal floor and ceiling effects on the subscales
hould permit measurement of change, both deterioration and
mprovement, in HRQoL. The MacNew consistently has been
hown to be responsive after different treatment options in pa-
ientswith angina,myocardial infarction, or ischemic heart failure
uch as cardiac rehabilitation [24,51–56], revascularization [57,58],
andmedication [59], andwe see no reasonwhy theMacNewwould
not be responsive in other patients with angina or ischemic heart
failure.
The results of this report in patients either with angina or isch-
emic heart failure demonstrate that the English version of the
MacNewmeets the psychometric standards for measurement, re-
liability, validity, interpretability, itemrelevance, andburden recom-
mended for HRQoL instruments [38], and, although responsiveness
could not be evaluated, this has been repeatedly demonstrated in
other studies in patientswith either angina or ischemic heart failure.
This study extends previous international validation studies in other
languages in patients with angina, MI, and ischemic heart failure
[24,26], substantiating the suggesting of the MacNew as a potential
core IHD-specific HRQoL instrument. A core IHD-specific HRQoL
questionnaire will provide a better understanding of the range in
HRQoL in patients with IHD that would potentially optimize clinical
service provision and clinical medicine and social science out-
come research efforts when assessing HRQoL or making HRQoL
outcome comparisons across patients with angina, MI, or isch-
emic heart failure.
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